PCN49 Biosimilar Trastuzumab Mono- and Pertuzumab Combination Therapy in Metastatic Breast Cancer: Cost Efficiency and Expanded Access Modeling
Pertuzumab
Biosimilar
Reimbursement
DOI:
10.1016/j.jval.2021.04.141
Publication Date:
2021-06-04T22:55:27Z
AUTHORS (4)
ABSTRACT
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (0)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....